Are there any new partnership, licensing, or co‑development agreements that could impact future revenue streams? | SLN (Aug 07, 2025) | Candlesense
SLN

Are there any new partnership, licensing, or co‑development agreements that could impact future revenue streams?

Based on the excerpt you provided from Silence Therapeutics’ Q2 2025 earnings release, the only specific highlight mentioned is the presentation of updated data on the company’s lead siRNA candidate — divesiran — at the recent European Hematology Association (EHA) meeting. The release does not reference any new partnership, licensing, or co‑development agreements, nor does it indicate that such arrangements were entered into during the quarter.

Therefore, according to the information supplied:

  • No new partnership, licensing, or co‑development agreements are disclosed that would affect future revenue streams.

If Silence Therapeutics had entered into any material collaborations during the quarter, those would typically be highlighted in the “Business Highlights” section of the earnings release. Since that section only mentions the encouraging data on divesiran, we can conclude that no such agreements were announced in this particular communication.

Other Questions About This News

What is the estimated market size for siRNA therapies in PV and related hematologic indications? How did the second‑quarter revenue and net loss compare to analyst consensus estimates? What is the current cash balance and projected cash‑burn rate, and how many months of runway does the company have? What regulatory hurdles or FDA/EMA milestones could affect the timeline to approval for divesiran? How might the Q2 results influence valuation multiples (e.g., EV/EBITDA, price‑to‑sales) for SLN compared to its peers? How does the company’s R&D spend as a percentage of revenue compare to other siRNA peers such as Alnylam or Dicerna? Are there any upcoming catalysts (e.g., conference presentations, data releases) that could drive the stock price in the near term? When is the next data read‑out or regulatory filing for divesiran in polycythemia vera expected? Did the company update its guidance for Q3 or full‑year 2025 earnings and cash flow? What are the implications of the recent EHA data on the probability of success for divesiran’s development program?